GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer medicines posted double digit ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GSK Plc raised its profit and sales forecasts for the year, aided by its HIV and immunology medicines, in Emma Walmsley’s ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...